Gene therapy for dyslipidemia: A review of gene replacement and gene inhibition strategies

Clinical Lipidology

Volumn 5, Issue 6, 2010, Pages 793-809

  Kassim, Sadik H ^a   Wilson, James M ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

dyslipidemia; gene therapy; lipoprotein

Indexed keywords

ABC TRANSPORTER A1; ADENOVIRUS VECTOR; ALIPOGENE TIPARVOVEC; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEIN; DIACYLGLYCEROL ACYLTRANSFERASE 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LENTIVIRUS VECTOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; PARVOVIRUS VECTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO; PRO 040201; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG TARGETING; DYSLIPIDEMIA; EX VIVO GENE TRANSFER; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GENE TRANSFER; HEPATOCYTE TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LOW FAT DIET; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; SIDE EFFECT; SOMATIC GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

EID: 79952131929     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.73     Document Type: Review

References (149)

1. Hegele RA: Plasma lipoproteins, genetic influences and clinical implications. Nat. Rev. Genet. 10, 109-121 (2009).
2. Lloyd-Jones D, Adams RJ, Brown TM et al.: Executive summary, Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121, E46-E215 (2010).
3. Dietz HC: Genomic medicine: new therapeutic approaches to mendelian disorders. N. Engl. J. Med. 363, 852-863 (2010).
4. Nguyen TH, Ferry N: Liver gene therapy: advances and hurdles. Gene Ther. 11, S76-S84 (2004). (Pubitemid 39359451)
5. Ross CJD, Twisk J, Meulenberg JM et al.: Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum. Gene Ther. 15, 906-919 (2004). (Pubitemid 39244845)
6. Athanasopulos T, Owen JS, Hassall DG et al.: Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice. Hum. Mol. Genet. 9, 2545-2551 (2000).
7. Shyh-Dar L, Song L, Leaf H: Lipoplex and LPD nanoparticles for in vivo gene delivery. Cold Spring Harb. Protoc. DOI:10.1101/pdb. prot4448 (2006) (Epub ahead of print).
8. Li SD, Huang L: Gene therapy progress and prospects: nonviral gene therapy by systemic delivery. Gene Ther. 13, 1313-1319 (2006). (Pubitemid 44323687)
9. Budker V, Zhang G, Knechtle S, Wolff JA: Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther. 3, 593-598 (1996). (Pubitemid 26258274)
10. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358 (2003). (Pubitemid 36538359)
11. Jooss K, Ertl HCJ, Wilson JM: Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72, 2945-2954 (1998). (Pubitemid 28175532)
12. Kay MA, Meuse L, Gown AM et al.: Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Natl Acad. Sci. USA 94, 4686-4691 (1997). (Pubitemid 27194304)
13. Yang Y, Su Q, Grewal IS et al.: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70, 6370-6377 (1996). (Pubitemid 26266857)
14. Seiler MP, Cerullo V, Lee B: Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 7, 297-305 (2007). (Pubitemid 47595772)
15. Flotte TR: New AAV serotypes may broaden the therapeutic pipeline to human gene therapy. Mol. Ther. 13, 1-2 (2006). (Pubitemid 41763477)
16. Gao G, Vandenberghe LH, Wilson JM: New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297 (2005). (Pubitemid 40895013)
17. Gao G, Alvira MR, Somanathan S et al.: Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl Acad. Sci. USA 100, 6081-6086 (2003). (Pubitemid 36576934)
18. Wang L, Wang H, Bell P et al.: Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol. Ther. 18, 118-125 (2010).
19. Wang L, Calcedo R, Wang H et al.: The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol. Ther. 18, 126-134 (2010).
20. Gao G, Vandenberghe LH, Alvira MR et al.: Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004). (Pubitemid 38715936)
21. Chao HJ, Liu YB, Rabinowitz J et al.: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2, 619-623 (2000).
22. Blankinship MJ, Gregorevic P, Allen JM et al.: Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10, 671-678 (2004). (Pubitemid 39272856)
23. McCarty DM: Self-complementary AAV vectors: advances and applications. Mol. Ther. 16, 1648-1656 (2008).
24. Crooke ST: Progress in antisense technology. Ann. Rev. Med. 61-95 (2004). (Pubitemid 38316716)
25. Lee SH, Sinko PJ: SiRNA - getting the message out. Eur. J. Pharm. Sci. 27, 401-410 (2006). (Pubitemid 43363336)
26. Sontheimer EJ: Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell Biol. 6, 127-138 (2005). (Pubitemid 40215808)
27. Haasnoot J, Berkhout B: Nucleic acids-based therapeutics in the battle against pathogenic viruses. Handb. Exp. Pharmacol. (189), 243-263 (2009).
28. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006). (Pubitemid 44050158)
29. Giering JC, Grimm D, Storm TA, Kay MA: Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther. 16, 1630-1636 (2008).
30. Ginsburg GS: Regression of atherosclerosis with therapeutic antibodies: pipe cleaner or pipe dream? J. Am. Coll. Cardiol. 50, 2319-2321 (2007).
31. Rader DJ, Cohen J, Hobbs HH: Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111, 1795-1803 (2003). (Pubitemid 38057721)
32. Moorjani S, Roy M, Gagne C et al.: Homozygous familial hypercholesterolemia among French Canadians in Quebec province. Arteriosclerosis 9, 211-216 (1989). (Pubitemid 19092104)
33. Khachadu Ak, Uthman SM: Experiences with homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutrition Metab. 15, 132-140 (1973).
34. Seftel HC, Baker SG, Sandler MP et al.: A host of hypercholesterolemic homozygotes in South Africa. BMJ 281, 633-636 (1980). (Pubitemid 10051766)
35. Goldstein JL, Brown MS: The LDL receptor defect in familial hypercholesterolemia: implications for pathogenesis and therapy. Med. Clin. N. Am. 66, 335-362 (1982). (Pubitemid 12115370)
36. Kolansky DM, Cuchel M, Clark BJ et al.: Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1438-1443 (2008).
37. Moghadasian MH, Frohlich JJ, Saleem M et al.: Surgical management of dyslipidemia: clinical and experimental evidence. J. Invest. Surg. 14, 71-78 (2001). (Pubitemid 32529847)
38. López-Santamaria M, Migliazza L, Gamez M et al.: Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal pass. J. Pediatr. Surg. 35, 630-633 (2000). (Pubitemid 30181048)
39. Thompsen J, Thompson PD: A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189, 31-38 (2006). (Pubitemid 44444914)
40. Sachais BS, Katz J, Ross J, Rader DJ: Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J. Clin. Apher. 20, 252-255 (2005).
41. Grossman M, Rader DJ, Muller DWM et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1, 1148-1154 (1995).
42. Grossman M, Raper SE, Kozarsky K et al.: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6, 335-341 (1994). (Pubitemid 24190015)
43. Daugherty A: Mouse models of atherosclerosis. Am. J. Med. Sci. 323, 3-10 (2002). (Pubitemid 34650115)
44. Rader DJ, Tietge UJ: Gene therapy for dyslipidemia: clinical prospects. Curr. Atheroscler. Rep. 1, 58-69 (1999).
45. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468-471 (1992).
46. Kozarsky KF, Jooss K, Donahee M, Strauss III JF, Wilson JM: Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat. Genet.13, 54-62 (1996). (Pubitemid 26139294)
47. Kozarsky KF, McKinley DR, Austin LL et al.: In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269, 13695-13702 (1994). (Pubitemid 24206152)
48. Chen SJ, Rader DJ, Tazelaar J et al.: Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol. Ther. 2, 256-261 (2000).
49. Lebherz C, Gao G, Louboutin JP et al.: Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6, 663-672 (2004). (Pubitemid 40228082)
50. Kankkonen HM, Vähäkangas E, Marr RA et al.: Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol. Ther. 9, 548-556 (2004). (Pubitemid 38578805)
51. Nomura S, Merched A, Nour E et al.: Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther. 11, 1540-1548 (2004). (Pubitemid 39359462)
52. Williams KJ, Feig JE, Fisher EA: Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat. Clin. Pract. Cardiovasc. Med. 5, 91-102 (2008). (Pubitemid 351168064)
53. Sadik H, Kassim HL, Luk H et al.: Rader gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 5(10), E13424 (2010).
54. Hibbitt OC, Harbottle RP, Waddington SN et al.: Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J. Gene Med. 9, 488-497 (2007). (Pubitemid 47007415)
55. Hibbitt OC, McNeil E, Lufino MMP et al.: Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs. Mol. Ther. 18, 317-326 (2010).
56. Crooke RM: Antisense oligonucleotides as therapeutics for hyperlipidaemias. Exp. Opin. Biol. Ther. 5, 907-917 (2005). (Pubitemid 41032848)
57. Crooke RM, Graham MJ, Lemonidis KM et al.: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
58. Raal FJ, Santos RD, Blom DJ et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia, a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
59. Visser ME, Akdim F, Tribble DL et al.: Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057-1062 (2010).
60. Visser ME, Kastelein JJP, Stroes ESG: Apolipoprotein B synthesis inhibition: results from clinical trials. Curr. Opin. Lipidol. (2010).
61. Akdim F, Visser ME, Tribble DL et al.: Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105, 1413-1419 (2010).
62. Akdim F, Stroes ES, Sijbrands EJ et al.: Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55(15), 1611-1618 (2010).
63. Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004). (Pubitemid 39545841)
64. Zimmermann TS, Lee ACH, Akinc A et al.: RNAi-mediated gene silencing in nonhuman primates. Nature 441, 111-114 (2006).
65. MacLachlan I: A Phase I study to evaluate the safety, tolerability, and pharmacokinetics of lipid nanoparticle ApoB siRNA (ApoB-SNALP) in hypercholesterolemic subjects. Presented at: American Society of Gene & Cell Therapy 13th Annual Conference. Washington, DC, USA, 17-22 May 2010.
66. Kotowski IK, Pertsemlidis A, Luke A et al.: A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410-422 (2006). (Pubitemid 43291224)
67. Abifadel M, Varret M, Rabès JP et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003). (Pubitemid 36666925)
68. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
69. Frank-Kamenetsky M, Grefhorst A, Anderson NN et al.: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105, 11915-11920 (2008).
70. Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116, 3090-3100 (2006). (Pubitemid 44878620)
71. Alwaili K, Awan Z, Alshahrani A, Genest J: High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev. Cardiovasc. Ther. 8, 413-423 (2010).
72. Sviridov D, Nestel PJ: Genetic factors affecting HDL levels, structure, metabolism and function. Curr. Opin. Lipidol. 18, 157-163 (2007). (Pubitemid 46412086)
73. Moore RE, Kawashiri MA, Kitajima K et al.: Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler. Thromb. Vasc. Biol. 23, 1914-1920 (2003). (Pubitemid 37254884)
74. Moore RE, Navab M, Millar JS et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circulation Res. 97, 763-771 (2005). (Pubitemid 41447126)
75. Kopfler WP, Willard M, Betz T et al.: Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 90, 1319-1327 (1994). (Pubitemid 24284453)
76. De Geest B, Zhao Z, Collen D, Holvoet P: Effects of adenovirus-mediated human apoA-I gene transfer on neointima formation after endothelial denudation in apoE-deficient mice. Circulation 96, 4349-4356 (1997). (Pubitemid 28007465)
77. Tsukamoto K, Hiester KG, Smith P et al.: Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J. Lipid Res. 38, 1869-1876 (1997). (Pubitemid 27411278)
78. Benoit P, Emmanuel F, Caillaud JM et al.: Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation 99, 105-110 (1999). (Pubitemid 29035964)
79. Tangirala RK, Tsukamoto K, Chun SH et al.: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100, 1816-1822 (1999). (Pubitemid 29498389)
80. De Geest B, Van Linthout S, Lox M, Collen D, Holvoet P: Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice, Role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum. Gene Ther. 11, 101-112 (2000). (Pubitemid 30044044)
81. Belalcazar LM, Merched A, Carr B et al.: Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 107, 2726-2732 (2003). (Pubitemid 36667248)
82. Pastore L, Belalcazar LM, Oka K et al.: Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 327, 153-160 (2004). (Pubitemid 38230111)
83. Sharifi BG, Wu K, Wang L et al.: AAV serotype-dependent apolipoprotein A-IMilano gene expression. Atherosclerosis 181, 261-269 (2005). (Pubitemid 41019606)
84. Kitajima K, Marchadier DHL, Burstein H, Rader DJ: Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis 186, 65-73 (2006).
85. Vaessen SFC, Veldman RJ, Cornijn EM et al.: AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency. J. Gene Med. 11, 697-707 (2009).
86. Cimmino G, Chen W, Speidl WS et al.: Safe and sustained overexpression of functional apolipoprotein-AI/high-density lipoprotein in apolipoprotein-AI-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. J. Cardiovasc. Pharmacol. 54, 405-411 (2009).
87. Weisgraber KH, Bersot TP, Mahley RW: A-I(Milano) apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J. Clin. Invest. 66, 901-907 (1980). (Pubitemid 11233788)
88. Gualandri V, Franceschini G, Sirtori CR: AI(Milano) apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am. J. Hum. Genet. 37, 1083-1097 (1985). (Pubitemid 16145258)
89. Chiesa G, Sirtori CR: Recombinant apolipoprotein A-IMilano: a novel agent for the induction of regression of atherosclerotic plaques. Ann. Med. 35, 267-273 (2003). (Pubitemid 36791694)
90. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ: Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc. Diabetol. 6, 15 (2007).
91. Alexander ET, Weibel GL, Joshi MR et al.: Macrophage reverse cholesterol transport in mice expressing ApoA-I milano. Arterioscler. Thromb. Vasc. Biol. 29, 1496-1501 (2009).
92. Santamarina-Fojo S, Peterson K, Knapper C et al.: Complete genomic sequence of the human ABCA1 gene. Analysis of the human and mouse ATP-binding cassette A promoter. Proc. Natl Acad. Sci. USA 97, 7987-7992 (2000). (Pubitemid 30460760)
93. Iatan I, Alrasadi K, Ruel I, Alwaili K, Genest J: Effect of ABCA1 mutations on risk for myocardial infarction. Curr. Atheroscler. Rep. 10, 413-426 (2008).
94. Schaefer EJ, Zech LA, Schwartz DE, Brewer HB: Coronary heart-disease prevalence and other clinical-features in familial high-density lipoprotein deficiency (tangier disease). Ann. Intern. Med. 93, 261-266 (1980). (Pubitemid 10044708)
95. Tall AR, Wang N: Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest. 106, 1205-1207 (2000).
96. Wang X, Collins HL, Ranalletta M et al.: Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117, 2216-2224 (2007). (Pubitemid 47219566)
97. Aiello RJ, Brees D, Bourassa PA et al.: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22, 630-637 (2002). (Pubitemid 34408745)
98. Wellington CL, Brunham LR, Zhou S et al.: Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J. Lipid Res. 44, 1470-1480 (2003). (Pubitemid 37279591)
99. Feng Y, Lievens J, Jacobs F et al.: Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis. Cardiovasc. Res. 88(2), 376-385 (2010).
100. Joyce CW, Wagner EM, Basso F et al.: ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J. Biol. Chem. 281, 33053-33065 (2006). (Pubitemid 46036688)
101. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT: Lecithin: cholesterol acyltransferase - from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 163-171 (2009).
102. Sakai N, Vaisman BL, Koch CA et al.: Targeted disruption of the mouse lecithin: cholesterol acyltransferase (LCAT) gene: generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 272, 7506-7510 (1997). (Pubitemid 27166465)
103. Broedl UC, Rader DJ: Gene therapy for lipoprotein disorders. Exp. Opin. Biol. Ther. 5, 1029-1038 (2005). (Pubitemid 41170033)
104. Séguret-Macé S, Latta-Mahieu M, Castro G et al.: Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 94, 2177-2184 (1996). (Pubitemid 26360511)
105. Mertens A, Verhamme P, Bielicki JK et al.: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice, LCAT gene transfer decreases atherosclerosis. Circulation 107, 1640-1646 (2003). (Pubitemid 36397333)
106. Van Craeyveld E, Lievens J, Jacobs F et al.: Apolipoprotein A-I and lecithin, Cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther. 16, 757-765 (2009).
107. Rader DJ, Daugherty A: Translating molecular discoveries into new therapies for atherosclerosis. Nature 451, 904-913 (2008). (Pubitemid 351301745)
108. Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007). (Pubitemid 350146106)
109. Bhatt KN, Wells BJ, Sperling LS, Baer JT: High-density lipoprotein therapy: is there hope? Curr. Treat. Options Cardiovasc. Med. 1-14 (2010).
110. Tanaka H, Ishida T, Johnston TP et al.: Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia. J. Atheroscler. Thromb. 16, 327-338 (2009).
111. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ: Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J. Clin. Invest. 111, 357-362 (2003). (Pubitemid 36182212)
112. Ishida T, Choi S, Kundu RK et al.: Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 111, 347-355 (2003). (Pubitemid 36182211)
113. Edmondson AC, Brown RJ, Kathiresan S et al.: Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J. Clin. Invest. 119, 1042-1050 (2009).
114. Garg A, Simha V: Update: update on dyslipidemia. J. Clin. Endocrinol. Metab. 92, 1581-1589 (2007). (Pubitemid 46997154)
115. Beigneux AP, Davies BSJ, Gin P et al.: Glycosylphosphatidylinositol- anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 5, 279-291 (2007). (Pubitemid 46477852)
116. Peterfy M, Ben-Zeev O, Mao HZ et al.: Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat. Genet. 39, 1483-1487 (2007). (Pubitemid 350191343)
117. Rahalkar AR, Giffen F, Har B et al.: Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can. J. Physiol. Pharmacol. 87, 151-160 (2009).
118. Banks PA: Practice guidelines in acute pancreatitis. Am. J. Gastroenterol. 92, 377-386 (1997). (Pubitemid 27108167)
119. Ashbourne Excoffon KJD, Liu G, Miao L et al.: Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 17, 2532-2539 (1997). (Pubitemid 28015990)
120. Liu G, Ashbourne Excoffon KJD, Wilson JE et al.: Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum. Gene Ther. 11, 21-32 (2000). (Pubitemid 30044037)
121. Groenemeijer BE, Hallman MD, Reymer PW et al.: Genetic variant showing a positive interaction with b-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation 95(12), 2628-2635. (1997). (Pubitemid 27255491)
122. Gagné SE, Larson MG, Pimstone SN et al.: A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin. Genet. 55(6), 450-454 (1999). (Pubitemid 29335642)
123. Wittrup HH, Tybjaerg-Hansen A, Steffensen R et al.: Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men, The Copenhagen city heart study. Arterioscler. Thromb. Vasc. Biol. 19, 1535-1540 (1999). (Pubitemid 29263025)
124. Ross CJD, Twisk J, Bakker AC et al.: Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum. Gene Ther. 17, 487-499 (2006). (Pubitemid 43794488)
125. Mingozzi F, Meulenberg JJ, Hui DJ et al.: AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114, 2077-2086 (2009).
126. Pennacchio LA, Olivier M, Hubacek JA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169-173 (2001). (Pubitemid 32952971)
127. Tai ES, Ordovas JM: Clinical significance of apolipoprotein A5. Curr. Opin. Lipidol. 19, 349-354 (2008).
128. Van der Vliet HN, Schaap FG, Levels JHM et al.: Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Comm. 295, 1156-1159 (2002).
129. Huang W, Bi N, Zhang X et al.: Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice. Biochem. Biophys. Res. Comm. 346, 14-18 (2006). (Pubitemid 43865962)
130. Hofker MH: APOC3 null mutation affects lipoprotein profile APOC3 deficiency, from mice to man. Eur. J. Hum. Genet. 18, 1-2 (2010).
131. Smith SJ, Cases S, Jensen DR et al.: Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat. Genet. 25, 87-90 (2000). (Pubitemid 30257043)
132. Yu XX, Murray SF, Pandey SK et al.: Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362-371 (2005). (Pubitemid 41061089)
133. Liu Y, Millar JS, Cromley DA et al.: Knockdown of Acyl-CoA: diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim. Biophys. Acta 1781, 97-104 (2008).
134. Ishibashi S, Brown MS, Goldstein JL et al.: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893 (1993). (Pubitemid 23262411)
135. Williams KJ, Fless GM, Petrie KA et al.: Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. 267, 13284-13292 (1992).
136. Signori E, Rinaldi M, Fioretti D et al.: ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. Biochem. Biophys. Res. Comm. 361, 543-548 (2007). (Pubitemid 47193118)
137. Evans V, Foster H, Graham IR et al.: Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7). Hum. Gene Ther. 19, 569-578 (2008). (Pubitemid 351913528)
138. Stevenson SC, Marshall-Neff J, Teng B et al.: Phenotypic correction of hypercholesterolemia in ApoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler. Thromb. Vasc. Biol. 15, 479-484 (1995).
139. Kashyap VS, Santamarina-Fojo S, Brown DR et al.: Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J. Clin. Invest. 96, 1612-1620 (1995).
140. Tsukamoto K, Smith P, Glick JM, Rader DJ: Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice. J. Clin. Invest. 100, 107-114 (1997). (Pubitemid 27311248)
141. Kim IH, Józkowicz A, Piedra PA, Oka K, Chan L: Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl Acad. Sci. USA 98, 13282-13287 (2001). (Pubitemid 33051354)
142. Tangirala RK, PraticóD, FitzGerald GA et al.: Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J. Biol. Chem. 276, 261-266 (2001). (Pubitemid 32050315)
143. Zamel R, Khan R, Pollex RL, Hegele RA: Abetalipoproteinemia: two case reports and literature review. Orphanet J. Rare Dis. 3, 19 (2008).
144. Sharp D, Blinderman L, Combs KA et al.: Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365, 65-69 (1993). (Pubitemid 23305570)
145. Stroes ES, Nierman MC, Meulenberg JJ et al.: Intramuscular administration of AAV1-lipoprotein lipaseS447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303-2304 (2008).
146. Tekmira Pharmaceuticals Completes ApoB SNALP Phase I Clinical Trial. Tekmira Pharmaceuticals www.tekmirapharm.com/News-and-Events/News-Releases/ Tekmira01071001.aspx
147. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report) National Institutes of Health (2002) www.nhlbi.nih.gov/guidelines/cholesterol/profmats.htm
148. Singh VN, Citkowitz E: Low HDL Cholesterol (Hypoalphalipoproteinemia). Medscape (2009) http://emedicine.medscape.com/article/127943-overview
149. Carrié A: LCAT deficiency (2006). www.orphanet.net/consor/cgi-bin/